Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|March 21, 2001
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virusF Le Guerhier, C Pichoud, C Jamard, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replicationS Aguesse-Germon, S H Liu, M Chevallier, et al.
Gut|January 14, 2003
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrenceT Bizollon, S N S Ahmed, S Radenne, et al.
Journal of Hepatology|June 1, 1997
Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatomaC Gouillat, D Manganas, F Zoulim, et al.
The Journal of General Virology|July 18, 2008
Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vectorJ Lucifora, D Durantel, L Belloni, et al.
Gene Therapy|June 26, 2001
Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liverM Robaczewska, S Guerret, J S Remy, et al.
Journal of Viral Hepatitis|February 7, 2013
New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern IndiaS Ghosh, P Banerjee, P Deny, et al.
Gastroenterologie Clinique Et Biologique|April 12, 2008
Long-term results of liver transplantation for Wilson's diseaseV Pabón, J Dumortier, R Gincul, et al.
Oncogene|August 8, 2017
Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virusM-L Plissonnier, T Lahlali, M Raab, et al.
Journal of Viral Hepatitis|April 17, 2018
Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western AfricaA Boyd, R Moh, S Maylin, et al.
Pageof 14